Roundtable Discussion: Designing the Right Clinical Trial Strategy for Amylin Therapeutics

4:00 pm - Wednesday 2nd December 2026

  • Compare how developers are approaching patient selection, from GLP-1 non responders and intolerant patients to first-line treatment populations
  • Debate which endpoints beyond headline weight loss will be most valuable, including body composition, metabolic outcomes, quality of life and weight maintenance
  • Discuss when placebo remains appropriate versus when active GLP-1 comparators are needed to demonstrate meaningful differentiation
  • Share how trial design should evolve across monotherapy, combination strategies and different intended product profiles